Opinion|Videos|July 5, 2024
Updates From the Phase 2 MonumenTAL-2 Study Investigating Talquetamab in R/R MM
Hans Lee, MD, discusses recent updates from the MonumenTAL-2 study investigating talquetamab in patients with relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Please comment on recent updates from the MonumenTAL-2 study investigating talquetamab.
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5